Investigators compared early oncologic outcomes by staging modality among men diagnosed with very high-risk prostate cancer.

Last month, former President Joe Biden announced that he had been diagnosed with an aggressive form of prostate cancer. The news sparked a larger conversation about what exactly the best practices are ...

CHICAGO — Prostate-specific antigen (PSA) levels could help guide treatment decisions for patients with metastatic hormone-sensitive prostate cancer, according to real-world findings from the ...

Urologist Dr. Jamin Brahmbhatt knows the complexities surrounding prostate-specific antigen testing with his patients. Here’s what to consider with the PSA test.

Prostate cancer highlights from AUA 2025 include quality-of-life results from the phase 3 PSMAfore study, findings on ADT with or without darolutamide, and data on the PSMA-targeted radionuclide J591.

Researchers have identified a new set of urine-based biomarkers that can accurately detect both the presence and severity of prostate cancer as an alternative to a PSA test, aiding early diagnosis.

The objective of this study is to develop a dual drug conjugate with a prostate-specific antigen (PSA) peptide recognition sequence for PC-specific combination SN-38 and cabazitaxel delivery in the ...

The incidence of prostate cancer is increasing. Screening with an assay of prostate-specific antigen (PSA) has a high rate for false positive results. Genomewide association studies have identified ...

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment.

Lutetium177-prostate-specific membrane antigen (PSMA) is effective for the treatment of men with mCRPC and PSMA-expressing disease identified on PET imaging.

The following is a summary of “Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings,” published in the March ...